Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17133388 | CONJUGATED BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND METHODS | December 2020 | April 2024 | Allow | 40 | 4 | 0 | Yes | No |
| 17128241 | NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES | December 2020 | September 2023 | Abandon | 33 | 2 | 0 | No | No |
| 17127697 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE | December 2020 | October 2023 | Abandon | 34 | 2 | 0 | No | No |
| 17124972 | B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES | December 2020 | September 2022 | Allow | 21 | 0 | 0 | Yes | No |
| 17251147 | CONJUGATES WITH INTERNAL AND TERMINAL-END HEPAROSAN LINKAGES | December 2020 | April 2024 | Abandon | 40 | 1 | 0 | No | No |
| 15734116 | COMPOSITIONS AND METHODS FOR TARGETED IMMUNOTHERAPY | December 2020 | April 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17105402 | ANTI-CD71 ACTIVATABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | November 2020 | October 2021 | Abandon | 10 | 1 | 0 | Yes | No |
| 17103866 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLS | November 2020 | August 2023 | Allow | 33 | 1 | 0 | Yes | Yes |
| 17057486 | MOLECULAR ADJUVANT | November 2020 | June 2024 | Abandon | 43 | 0 | 1 | No | No |
| 16950522 | ANTI-CD117 ANTIBODIES AND CONJUGATES | November 2020 | September 2022 | Allow | 22 | 0 | 0 | Yes | No |
| 17089227 | Saccharide Derivative of a Toxic Payload and Antibody Conjugates Thereof | November 2020 | August 2023 | Abandon | 33 | 0 | 1 | No | No |
| 17078467 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | October 2020 | December 2022 | Allow | 26 | 0 | 0 | Yes | No |
| 17074387 | SITE-SPECIFIC QUANTITATION OF DRUG CONJUGATIONS | October 2020 | May 2023 | Allow | 31 | 1 | 1 | No | No |
| 17036138 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | September 2020 | February 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 17037370 | Drug-Conjugates With a Targeting Molecule and Two Different Drugs | September 2020 | January 2024 | Allow | 39 | 2 | 0 | No | Yes |
| 17006926 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | August 2020 | March 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17006954 | COMPOSITIONS, ARTICLES OF MANUFACTURE AND METHODS FOR TREATING CANCER | August 2020 | March 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17006881 | CONJUGATED BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND METHODS | August 2020 | July 2024 | Abandon | 47 | 0 | 1 | No | No |
| 16996780 | FORMULATIONS OF TESTOSTERONE AND METHODS OF TREATMENT THEREWITH | August 2020 | August 2023 | Allow | 35 | 2 | 0 | No | No |
| 16992453 | Anti-STEAP2 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind STEAP2 and CD3, and Uses Thereof | August 2020 | December 2022 | Allow | 28 | 0 | 0 | Yes | No |
| 16990330 | ANTI-GPR20 ANTIBODY AND ANTI-GPR20 ANTIBODY-DRUG CONJUGATE | August 2020 | September 2020 | Allow | 1 | 0 | 0 | Yes | No |
| 16945069 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | July 2020 | February 2023 | Abandon | 30 | 1 | 0 | No | No |
| 16934955 | ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF | July 2020 | November 2023 | Abandon | 40 | 2 | 0 | No | No |
| 16958463 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | June 2020 | April 2023 | Allow | 33 | 2 | 1 | No | No |
| 16914112 | ANTI-CD8 ANTIBODIES AND USES THEREOF | June 2020 | July 2022 | Allow | 25 | 0 | 0 | Yes | No |
| 16910921 | INHIBITORS OF IMMUNE CHECKPOINT MODULATORS AND RELATED METHODS | June 2020 | March 2023 | Abandon | 32 | 2 | 0 | No | No |
| 15733309 | ONE-POT PROCESS FOR PREPARING INTERMEDIATE OF ANTIBODY-DRUG CONJUGATE | June 2020 | May 2023 | Allow | 34 | 2 | 0 | Yes | Yes |
| 16906985 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | June 2020 | December 2022 | Allow | 30 | 1 | 0 | No | No |
| 16955477 | COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND IDO1 INHIBITOR FOR THE TREATMENT OF CANCER | June 2020 | September 2023 | Abandon | 39 | 1 | 1 | No | No |
| 16896930 | MUTANT ANTIBODIES AND CONJUGATION THEREOF | June 2020 | May 2023 | Allow | 35 | 0 | 1 | Yes | No |
| 16771124 | GENERATION-DEPENDENT SUPRAMOLECULAR ASSEMBLIES OF PROTEIN-DENDRON CONJUGATES | June 2020 | May 2023 | Allow | 35 | 2 | 2 | Yes | No |
| 16894602 | ENEDIYNE CONJUGATES | June 2020 | August 2022 | Allow | 27 | 1 | 0 | Yes | No |
| 16769993 | INTRACELLULAR DELIVERY OF BIOMOLECULES TO MODULATE ANTIBODY PRODUCTION | June 2020 | October 2023 | Abandon | 41 | 2 | 1 | No | No |
| 16892529 | CD48 ANTIBODIES AND CONJUGATES THEREOF | June 2020 | December 2022 | Abandon | 31 | 1 | 0 | No | No |
| 16892467 | Methods of Treating or Preventing an Attention Disorder, Cognitive Disorder, and/or Dementia Associated with a Neurodegenerative Disorder | June 2020 | April 2023 | Allow | 35 | 1 | 1 | No | No |
| 16767804 | FUSION PROTEIN COMPRISING GLUTATHIONE-S-TRANSFERASE AND PROTEIN HAVING BINDING AFFINITY TARGET CELL OR TARGET PROTEIN, AND USE THEREOF | May 2020 | July 2023 | Allow | 38 | 2 | 0 | Yes | No |
| 16763814 | PYRROLOBENZODIAZEPINE CONJUGATES | May 2020 | September 2022 | Allow | 28 | 0 | 0 | Yes | No |
| 16763776 | MULTIFUNCTIONAL IMMUNE CELL THERAPIES | May 2020 | March 2023 | Allow | 34 | 0 | 1 | Yes | No |
| 16870853 | COMBINATION THERAPY WITH NOTCH AND PD-1 OR PD-L1 INHIBITORS | May 2020 | July 2023 | Allow | 38 | 4 | 0 | No | No |
| 16868365 | METHODS FOR TREATING HYPERSOMNIA | May 2020 | December 2022 | Abandon | 31 | 1 | 0 | No | No |
| 16867412 | METHOD OF TREATING HAND-FOOT SYNDROME AND SYMPTOMS ASSOCIATED THEREWITH | May 2020 | September 2023 | Abandon | 40 | 2 | 0 | Yes | No |
| 16853619 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CELLS | April 2020 | November 2023 | Abandon | 43 | 0 | 2 | No | No |
| 16849311 | Mitigating Necrosis in Transgenic Glyphosate-Tolerant Cotton Plants Treated with Herbicidal Glyphosate Formulations | April 2020 | May 2024 | Allow | 49 | 3 | 1 | No | No |
| 16311084 | KILLER CELL CAPABLE OF EFFICIENTLY AND STABLY EXPRESSING ANTIBODY, AND USES THEREOF | March 2020 | March 2024 | Allow | 60 | 1 | 3 | Yes | No |
| 16828279 | ANTIBODY-DRUG CONJUGATE | March 2020 | December 2022 | Allow | 32 | 1 | 0 | No | No |
| 16650226 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | March 2020 | November 2022 | Allow | 31 | 1 | 1 | Yes | No |
| 16649083 | THERAPEUTIC AGENTS SPECIFICALLY DELIVERED BY EXOSOMES FOR CANCER TREATMENT | March 2020 | August 2022 | Allow | 29 | 1 | 0 | No | No |
| 16803931 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | February 2020 | July 2023 | Abandon | 40 | 1 | 1 | No | No |
| 16642277 | NOVEL METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | February 2020 | December 2021 | Allow | 22 | 1 | 0 | No | No |
| 16796422 | NK-3 RECEPTOR ANTAGONISTS FOR THERAPEUTIC TREATMENT OF LEPTIN-RELATED DISEASE | February 2020 | June 2022 | Allow | 28 | 0 | 0 | Yes | No |
| 16793843 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | February 2020 | April 2022 | Allow | 26 | 0 | 0 | Yes | No |
| 16784069 | HUMANIZED ANTIBODIES TO LIV-1 AND USE OF SAME TO TREAT CANCER | February 2020 | September 2023 | Abandon | 43 | 1 | 1 | No | No |
| 16777513 | Use of Ureidomustine (BO-1055) in Cancer Treatment | January 2020 | October 2022 | Abandon | 32 | 1 | 0 | No | No |
| 16776395 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | January 2020 | September 2022 | Allow | 32 | 1 | 0 | Yes | No |
| 16774829 | POLYMER LINKERS AND THEIR USES | January 2020 | August 2022 | Allow | 30 | 1 | 0 | Yes | No |
| 16740570 | Use of Paeoniflorin-6'-O-benzenesulfonate in treatment of Sj�gren's syndrome | January 2020 | November 2023 | Abandon | 46 | 4 | 0 | No | No |
| 16740023 | 6-SUBSTITUTED AND 7-SUBSTITUTED MORPHINAN ANALOGS AND THE USE THEREOF | January 2020 | September 2023 | Abandon | 44 | 2 | 1 | No | No |
| 16740312 | BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES | January 2020 | January 2022 | Allow | 24 | 0 | 0 | Yes | No |
| 16629046 | CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATORY DOMAINS | January 2020 | May 2024 | Allow | 52 | 2 | 2 | Yes | Yes |
| 16696455 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | November 2019 | February 2023 | Allow | 39 | 1 | 1 | Yes | No |
| 16695239 | TETRAZOLONE-SUBSTITUTED DIHYDROPYRIDINONE MGAT2 INHIBITORS | November 2019 | June 2022 | Allow | 31 | 1 | 0 | No | No |
| 16689286 | PYRROLOBENZODIAZEPINE PRODRUGS AND ANTIBODY CONJUGATES THEREOF | November 2019 | October 2022 | Allow | 35 | 1 | 1 | No | No |
| 16684130 | NOVEL ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT | November 2019 | July 2022 | Abandon | 32 | 1 | 0 | No | No |
| 16683667 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | November 2019 | January 2022 | Allow | 26 | 0 | 0 | Yes | No |
| 16681306 | NOVEL ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT | November 2019 | October 2022 | Allow | 35 | 2 | 0 | No | No |
| 16679379 | METHOD OF TREATING COCAINE ADDICTION | November 2019 | February 2022 | Allow | 27 | 1 | 0 | No | No |
| 16674381 | METHOD OF TREATING POST-TRAUMATIC STRESS DISORDER | November 2019 | July 2023 | Allow | 45 | 0 | 1 | Yes | No |
| 16484290 | NON-PEPTIDIC POLYMERIC LINKER COMPOUND, CONJUGATE COMPRISING SAME LINKER COMPOUND, AND METHODS FOR PREPARING SAME LINKER COMPOUND AND CONJUGATE | October 2019 | November 2023 | Allow | 51 | 1 | 1 | No | No |
| 16658245 | MODULATORS OF RESISTANT ANDROGEN RECEPTOR | October 2019 | April 2023 | Allow | 42 | 1 | 1 | Yes | No |
| 16656273 | Methods of Reducing Mammographic Breast Density and/or Breast Cancer Risk | October 2019 | June 2022 | Abandon | 32 | 1 | 0 | No | No |
| 16605710 | COMBINATION THERAPY WITH AN ANTI-PSMA ANTIBODY-DRUG CONJUGATE | October 2019 | April 2022 | Abandon | 30 | 1 | 0 | No | No |
| 16605708 | COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY-DRUG CONJUGATE | October 2019 | July 2022 | Allow | 33 | 1 | 0 | No | No |
| 16605238 | MODIFIED CYTOMEGALOVIRUS PROTEINS AND STABILIZED COMPLEXES | October 2019 | June 2024 | Abandon | 56 | 1 | 1 | No | No |
| 16594728 | ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | October 2019 | February 2021 | Allow | 16 | 2 | 0 | Yes | No |
| 16590967 | COMBINATION THERAPY USING ANTI-SSEA-4 ANTIBODY IN COMBINATION WITH THERAPEUTIC ONCOLOGY AGENTS | October 2019 | March 2024 | Abandon | 53 | 4 | 0 | No | No |
| 16587720 | DELTA-OPIOID RECEPTOR TARGETED AGENT FOR MOLECULAR IMAGING AND IMMUNOTHERAPY OF CANCER | September 2019 | June 2022 | Abandon | 32 | 1 | 0 | No | No |
| 16586546 | CYCLOPHOSPHAMIDE ANALOGS FOR USE AS IMMUNOGENS AND ASSAY CONJUGATES FOR AN IMMUNOASSAY OF CYCLOPHOSPHAMIDE AND IFOSFAMIDE | September 2019 | April 2022 | Allow | 30 | 1 | 0 | Yes | No |
| 16584272 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | September 2019 | May 2022 | Abandon | 32 | 1 | 0 | No | No |
| 16582295 | DOCETAXEL ALBUMIN NANOPARTICLE PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | September 2019 | April 2022 | Allow | 31 | 1 | 0 | Yes | No |
| 16580178 | COMBINATION OF IMMUNOTHERAPEUTICS AND BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR TREATING LYMPHOMAS | September 2019 | November 2022 | Abandon | 38 | 2 | 1 | No | No |
| 16580505 | PHARMACEUTICAL COMBINATIONS | September 2019 | February 2022 | Allow | 29 | 1 | 0 | No | No |
| 16576395 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF SCHISTOSOMIASIS | September 2019 | February 2023 | Abandon | 40 | 2 | 0 | No | No |
| 16574500 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | September 2019 | November 2019 | Allow | 2 | 0 | 0 | Yes | No |
| 16491875 | CELL BASED METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENT DELIVERY AND TREATMENTS USING SAME | September 2019 | August 2022 | Abandon | 35 | 1 | 0 | No | No |
| 16563507 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | September 2019 | June 2022 | Abandon | 33 | 1 | 0 | No | No |
| 16489455 | COMPOSITIONS AND METHODS FOR CAR T CELL THERAPY | August 2019 | July 2023 | Allow | 47 | 2 | 1 | Yes | No |
| 16487419 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS FOR PHOTOIMMUNOTHERAPY | August 2019 | March 2023 | Abandon | 43 | 3 | 0 | Yes | No |
| 16537244 | 3-ALKYL PYRIDINIUM COMPOUND FROM RED SEA SPONGE WITH POTENT ANTIVIRAL ACTIVITY | August 2019 | August 2022 | Abandon | 36 | 4 | 1 | Yes | No |
| 16534903 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | August 2019 | March 2023 | Abandon | 43 | 1 | 1 | No | No |
| 16482836 | DOSING SCHEDULE OF A WNT INHIBITOR AND AN ANTI-PD-1 ANTIBODY MOLECULE IN COMBINATION | August 2019 | March 2022 | Allow | 32 | 2 | 0 | No | No |
| 16475809 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | July 2019 | January 2024 | Abandon | 54 | 1 | 0 | No | No |
| 16456177 | DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY | June 2019 | May 2022 | Allow | 34 | 2 | 0 | No | Yes |
| 16470950 | AMANITIN ANTIBODY CONJUGATES | June 2019 | February 2022 | Allow | 32 | 1 | 0 | No | No |
| 16469768 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | June 2019 | September 2021 | Allow | 27 | 1 | 1 | Yes | No |
| 16437624 | Diagnostic System and Process for Rapid Bacterial Infection Diagnosis | June 2019 | March 2020 | Abandon | 9 | 1 | 0 | No | No |
| 16467450 | CYSTEINE PEPTIDE-ENABLED ANTIBODIES | June 2019 | March 2024 | Abandon | 57 | 3 | 1 | No | No |
| 16432244 | PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS | June 2019 | August 2022 | Allow | 38 | 1 | 1 | No | No |
| 16423976 | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE | May 2019 | January 2023 | Abandon | 43 | 2 | 0 | No | No |
| 16419971 | ANTIPROLIFERATIVE COMPOUNDS AND BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 FOR COMBINED USE | May 2019 | April 2022 | Allow | 35 | 2 | 0 | No | No |
| 16414895 | NOVEL ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT | May 2019 | August 2019 | Allow | 3 | 0 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PUTTLITZ, KARL J.
With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 23.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner PUTTLITZ, KARL J works in Art Unit 1642 and has examined 375 patent applications in our dataset. With an allowance rate of 61.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner PUTTLITZ, KARL J's allowance rate of 61.3% places them in the 23% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by PUTTLITZ, KARL J receive 2.20 office actions before reaching final disposition. This places the examiner in the 56% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by PUTTLITZ, KARL J is 32 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +43.4% benefit to allowance rate for applications examined by PUTTLITZ, KARL J. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 20.5% of applications are subsequently allowed. This success rate is in the 25% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 27.1% of cases where such amendments are filed. This entry rate is in the 39% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 46.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 87.5% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 71.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 59.8% are granted (fully or in part). This grant rate is in the 61% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.2% of allowed cases (in the 83% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.